Forget the headlines. The real worth of a post-market program for healthcare AI is found in the documentation that underpins its day-to-day operations. When a clinical or compliance lead is digging through post-market records for a cardiac AI tool, they’re looking for that paper trail because they know a real hazard record is built piece by piece from the routine, boring monitoring of a device’s lifecycle, not some sensational one-off event.
The ECRI Hazard Reporting frame really forces this document-first perspective, interpreting a post-market program by its verifiable, recorded signals instead of just anecdotal stories. This is the reality for companies like HeartFlow, Paige AI, and Anumana, whose entire post-market posture, from hazard reports to ongoing surveillance, is in the end judged by the quality and completeness of their documented compliance records.
The Foundational Pillars of Post-Market Documentation
A solid post-market program is built on a simple commitment: document everything. Long before a specific hazard ever gets a name, the real work is done by establishing processes and generating the records to prove they’re being followed. Those records are the only ground truth for analyzing a device’s safety and efficacy later on. Without them, any claims a vendor makes about performance or risk mitigation are just hot air.
In the world of cardiac AI, this documentation needs to cover some specific ground, like proving you’re following audit standards and, just as important, recording every single deviation and the corrective actions you took. There’s a well-worn saying that’s absolutely true for anyone dealing with regulatory scrutiny: if you didn’t write it down, it never happened. These tangible records are what give you an objective basis for evaluating a device’s ongoing safety profile, period.
Adverse Event Reporting and Post-Market Surveillance: The Active Record
Your quality systems are the foundation, but the active work of building a hazard record happens through things like Adverse Event Reporting and Post-Market Surveillance. These are continuous processes for capturing real-world performance data, not just something you do after a problem pops up. Both Post-Market Surveillance and Adverse Event Reporting are standard, recognized monitoring activities in clinical AI safety, which is why they’re part of the conversation for vendors like HeartFlow and Paige AI and why the FDA guidance on post-market surveillance for medical devices is so explicit about them.
Adverse Event Reporting is an especially loud signal for potential trouble, which is why it’s a key part of the safety record for cardiac devices from companies like Anumana and HeartFlow. Every single event that gets reported, no matter how minor it seems, is another entry into the device’s permanent record, building out its risk profile over time. Post-Market Surveillance does something similar by systematically gathering and analyzing performance, safety, and effectiveness data after a product is already out in the wild, and if you document that data stream correctly, you get a feedback loop that lets you spot trends or new hazards before they blow up.
Here’s the key takeaway: the event report itself is the record. The surveillance log is the record. A formal hazard might get identified later, but the documentation comes first. This is what separates a verifiable, actionable hazard record from just an anecdotal hazard story you might hear in the hallway.
Standard Signals in the Post-Market Frame
So what does the ECRI Hazard Reporting frame actually look for? It uses a set of standard signals to get a structured picture of a device’s post-market health, and these are tangible records that any clinical or compliance lead can track down without having to get the vendor on the phone. The specific recorded signals are things you can actually find and read: HIPAA Compliance Audits, FDA Quality System Inspection reports, IEC 62304 certifications, Adverse Event Reports, Post-Market Surveillance plans, and any documented Quality System Failures.
Some of these signals, like the FDA Quality System Inspection, are already part of the clearance record for any filed clinical AI device. You’ll see them pop up for companies like HeartFlow and Paige AI, and it’s important to know the FDA inspection is now aligning with the new Quality Management System Regulation (QMSR) that takes effect in February 2026. A documented Quality System Failure is another big one, it’s exactly what it sounds like, a documented breakdown in the vendor’s own safety processes. Then you have standards like the IEC 62304 standard for medical device software life cycle processes, which forces vendors to create a ton of documentation during development and maintenance, especially with its new Edition 2 that specifically calls out health software and AI/ML.
Using these recorded signals gives you a consistent way to evaluate different vendors’ post-market programs side-by-side. For a company like HeartFlow, you can pull up its FDA Quality System Inspection records (which, again, now fall under the QMSR) and put them right next to these other documented standards. It creates a standardized way to look at their compliance and operations, replacing subjective feelings with objective facts.
What a Reader Can Check Without a Vendor Conversation
The whole point of this document-first approach is that it’s transparent and verifiable, meaning clinical and compliance leads can do their own homework on a cardiac AI device’s post-market status. You can learn a ton just by looking at publicly available or auditable records. This cuts down your reliance on the vendor’s sales pitch and lets you focus on the objective evidence yourself.
For any of these companies, HeartFlow, Paige AI, Anumana, the proof is in these documented signals. You, as a reader, can go look for yourself: check the HIPAA Compliance Audits to see how they handle data security. Pull the FDA Quality System Inspection reports (remembering they’re now under QMSR, effective Feb 2026) to get a window into their quality control. Review their IEC 62304 compliance documents (especially with the new Edition 2 rules for AI/ML) to judge their software development discipline. Dig into Adverse Event Reporting databases for a raw history of reported problems. And read their Post-Market Surveillance summaries to see if they’re actually watching the device in the field. And if you find a documented Quality System Failure, you’ve found a clear record of past non-compliance and can check what they did to fix it.
Being able to follow each of these signals without having to book a meeting with the vendor is what allows you to do real due diligence. It hammers home the point that a hazard record is a factual account built from routine paperwork, not a story that a company tells you. For anyone trying to figure out the true regulatory posture and long-term viability of a cardiac AI tool, knowing how to read this paper trail is everything.
Frequently Asked Questions
What constitutes a ‘hazard record’ in post-market cardiac AI surveillance?
A hazard record is meticulously assembled from routine monitoring and documentation throughout a device’s lifecycle. It is not based on sensational events, but on verifiable, recorded signals from established processes and active monitoring capabilities like Adverse Event Reporting and Post-Market Surveillance. This documentation provides an objective basis for evaluating a device’s ongoing safety profile.
What is the significance of a ‘document-first approach’ for post-market programs in cardiac AI?
A document-first approach shifts the focus from anecdotal incidents to verifiable, recorded signals, forming the bedrock for analyzing device safety and efficacy. Without this foundational documentation, claims about post-market performance or hazard mitigation are unsubstantiated. It ensures that if something is not documented, it effectively did not happen in the eyes of regulatory scrutiny.
What are the foundational pillars of post-market documentation for cardiac AI devices?
The foundational pillars include a clear commitment to documentation, established processes with corresponding records, and adherence to audit standards with meticulous recording of deviations or corrective actions. This documentation encompasses critical areas that provide an objective basis for evaluating a device’s ongoing safety profile. It ensures that any claims about post-market performance are substantiated.
What ‘standard signals’ can clinical and compliance leads use to evaluate a cardiac AI device’s post-market standing without direct vendor engagement?
Clinical and compliance leads can follow standard signals such as HIPAA Compliance Audit, FDA Quality System Inspection (QMSR), IEC 62304, Adverse Event Reporting, Post-Market Surveillance, and Quality System Failure. These are tangible records that offer a consistent framework for evaluating post-market programs across different vendors. They allow for a standardized assessment of compliance and operational integrity.